BioMarin Pharmaceutical (BMRN)
NASDAQ:BMRN
Want to see BMRN full AI Analyst Report?
Total Valuation
BioMarin Pharmaceutical has a market cap or net worth of $10.01B. The enterprise value is $9.23B.
Market Cap$10.01B
Enterprise Value$9.23B
Share Statistics
BioMarin Pharmaceutical has 193,284,440 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding193,284,440
Owned by Insiders0.50%
Owned by Institutions36.51%
Financial Efficiency
BioMarin Pharmaceutical’s return on equity (ROE) is 0.06 and return on invested capital (ROIC) is 5.64%.
Return on Equity (ROE)0.06
Return on Assets (ROA)0.05
Return on Invested Capital (ROIC)5.64%
Return on Capital Employed (ROCE)0.08
Revenue Per Employee1.06M
Profits Per Employee114.77K
Employee Count3,040
Asset Turnover0.42
Inventory Turnover0.57
Valuation Ratios
The current PE Ratio of BioMarin Pharmaceutical is 25.8. BioMarin Pharmaceutical’s PEG ratio is -1.71.
PE Ratio25.8
PS Ratio3.54
PB Ratio1.87
Price to Fair Value1.87
Price to FCF15.72
Price to Operating Cash Flow11.41
PEG Ratio-1.71
Income Statement
In the last 12 months, BioMarin Pharmaceutical had revenue of 3.22B and earned 348.90M in profits. Earnings per share was 1.82.
Revenue3.22B
Gross Profit2.48B
Operating Income533.48M
Pretax Income482.48M
Net Income348.90M
EBITDA572.94M
Earnings Per Share (EPS)1.82
Cash Flow
In the last 12 months, operating cash flow was 874.25M and capital expenditures -107.19M, giving a free cash flow of 767.06M billion.
Operating Cash Flow874.25M
Free Cash Flow767.06M
Free Cash Flow per Share3.97
Dividends & Yields
BioMarin Pharmaceutical pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.54
52-Week Price Change-12.79%
50-Day Moving Average58.06
200-Day Moving Average56.56
Relative Strength Index (RSI)42.88
Average Volume (3m)1.77M
Important Dates
BioMarin Pharmaceutical upcoming earnings date is Aug 4, 2026, After Close (Confirmed).
Last Earnings DateMay 4, 2026
Next Earnings DateAug 4, 2026
Ex-Dividend Date―
Financial Position
BioMarin Pharmaceutical as a current ratio of 5.21, with Debt / Equity ratio of 23.17%
Current Ratio5.21
Quick Ratio3.50
Debt to Market Cap0.05
Net Debt to EBITDA-1.17
Interest Coverage Ratio48.95
Taxes
In the past 12 months, BioMarin Pharmaceutical has paid 133.58M in taxes.
Income Tax133.58M
Effective Tax Rate0.28
Enterprise Valuation
BioMarin Pharmaceutical EV to EBITDA ratio is 18.73, with an EV/FCF ratio of 14.80.
EV to Sales3.33
EV to EBITDA18.73
EV to Free Cash Flow14.80
EV to Operating Cash Flow12.96
Balance Sheet
BioMarin Pharmaceutical has $2.22B in cash and marketable securities with $1.44B in debt, giving a net cash position of $782.83M billion.
Cash & Marketable Securities$2.22B
Total Debt$1.44B
Net Cash$782.83M
Net Cash Per Share$4.05
Tangible Book Value Per Share$29.60
Margins
Gross margin is 75.93%, with operating margin of 16.56%, and net profit margin of 10.83%.
Gross Margin75.93%
Operating Margin16.56%
Pretax Margin14.98%
Net Profit Margin10.83%
EBITDA Margin17.79%
EBIT Margin15.32%
Analyst Forecast
The average price target for BioMarin Pharmaceutical is $87.41, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$87.41
Price Target Upside59.98% Upside
Analyst ConsensusModerate Buy
Analyst Count19
Revenue Growth Forecast12.53%
EPS Growth Forecast-49.09%